Skip to main content


Table 1 Trial schedule of patients and healthy controls

From: Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder

Visit (V)/Action SC BL V1 V2 V3 V4 V5 V6 V7 V8
Trial day -14-0 0 7 ± 2 14 ± 2 21 ± 2 28 ± 2 35 ± 2 42 ± 2 49 ± 2 56 ± 2
DIA-X-SSQ 1) X          
Basic documentation           
Inclusion/exclusion criteria   X         
Patient information and consent   X         
Demographics   X         
Medical history   X         
Diagnostic procedures           
M.I.N.I. SCID-II X2) X X3) X         
Treatment outcome           
HAMD-17 IDS-C30 IDS-SR30 SF-12   X X X X X X X X X
Peripheral blood           
Serum   X X X X X X X X X
Plasma   X X X X X X X X X
Whole blood (EDTA)   X X X X X X X X X
MWT   X         
RWT   X   X   X   X   X
TMT A/B   X   X   X   X   X
RWT (category change)   X   X       X
DOT   X   X       X
RFFT   X   X       X
End of trial           X
  1. 1) only in healthy controls; 2) in patients at screening visit; 3) in healthy controls at baseline visit; SC = Screening; BL = Baseline; V1 = Visit 1, V2 = Visit 2, V3 = Visit 3, V4 = Visit 4, V5 = Visit 5, V6 = Visit 6, V7 = Visit 7, V8 = Visit 8; DIA-X-SSQ = Screening Questionnaire of the DIA-X-Interview, M.I.N.I. = MINI International Neuropsychiatric Interview; SCID-II = Structured Clinical Interview for DSM-IV Axis II Personality Disorders; HAMD17 = Hamilton Depression Rating Scale; IDS-C30 = Inventory of Depressive Symptoms - Interview, IDS-SR30 = Inventory of Depressive Symptoms - Self rating, MWT = Multiple Vocabulary Test, TMT = Trail Making Test, DOT = Adaptive Digit Ordering Test, RFFT = Ruff Figural Fluency Test